LifeMD, Inc. (NASDAQ:LFMD) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of LifeMD, Inc. (NASDAQ:LFMD) have been given an average recommendation of “Moderate Buy” by the nine research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $9.25.

Several research firms recently commented on LFMD. Loop Capital set a $8.00 price objective on LifeMD in a report on Monday, November 24th. BTIG Research decreased their price objective on shares of LifeMD from $18.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Wall Street Zen cut shares of LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Lake Street Capital cut their target price on shares of LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Finally, Mizuho decreased their target price on shares of LifeMD from $8.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, November 19th.

Insider Activity at LifeMD

In other LifeMD news, CMO Jessica Friedeman sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $3.61, for a total value of $54,150.00. Following the transaction, the chief marketing officer directly owned 205,000 shares of the company’s stock, valued at approximately $740,050. This trade represents a 6.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 18.40% of the stock is owned by insiders.

Institutional Investors Weigh In On LifeMD

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new position in LifeMD during the fourth quarter valued at $36,000. Magnus Financial Group LLC purchased a new position in shares of LifeMD during the 4th quarter valued at about $41,000. Jain Global LLC purchased a new position in shares of LifeMD during the 4th quarter valued at about $45,000. Nisa Investment Advisors LLC grew its stake in shares of LifeMD by 148.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company’s stock valued at $50,000 after acquiring an additional 2,185 shares during the period. Finally, Quarry LP purchased a new stake in LifeMD in the 3rd quarter worth approximately $52,000. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $2.90 on Friday. The business has a fifty day moving average price of $3.43 and a 200-day moving average price of $4.99. The company has a market capitalization of $139.61 million, a PE ratio of -17.06 and a beta of 1.90. LifeMD has a 1-year low of $2.71 and a 1-year high of $15.84.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings data on Monday, November 17th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The business had revenue of $60.17 million for the quarter, compared to analyst estimates of $62.07 million. During the same period in the prior year, the company posted $0.09 EPS. On average, sell-side analysts anticipate that LifeMD will post -0.56 earnings per share for the current fiscal year.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.